[Pharmacokinetics, interactions and mechanism of action of maraviroc].

@article{Soriano2008PharmacokineticsIA,
  title={[Pharmacokinetics, interactions and mechanism of action of maraviroc].},
  author={Vicente Soriano and Eva Poveda},
  journal={Enfermedades infecciosas y microbiologia clinica},
  year={2008},
  volume={26 Suppl 11},
  pages={12-6}
}
Maraviroc (MVC, Celsentri) is an allosteric and reversible inhibitor of the CCR5 chemokine coreceptor. MVC is the first marketed CCR5 antagonist and the only oral entry inhibitor approved so far for the treatment of HIV infection. It has been approved for adults with previous antiretroviral exposure. MVC exclusively inhibits the replication of R5- tropic… CONTINUE READING